Key facts
- This page summarizes Ph.D. Vimal Mehta's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Mar 2022, 16:17.
Ph.D. Vimal Mehta - 14 Mar 2022 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)
- Reporting relationship
- CEO and President, Director
- Issuer ticker
- BTAI
- Reported as of
- 14 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Mar 2022, 16:17:41 UTC
- Prior SEC filing
- 14 Feb 2022
- Next SEC filing
- 17 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Javier Rodriguez, as Attorney in Fact for Vimal Mehta, Ph.D.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ph.D. Vimal Mehta filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 16 Mar 2022.
Change
- Previous filing in this sequence was filed on 14 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BTAI
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +41,750
- Change %
- Price
- $0.000000
- Shares after
- 41,750
- Date
- 14 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 41,750
- Exercise price
- Footnotes
- F1, F2
BTAI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +167,000
- Change %
- Price
- $0.000000
- Shares after
- 167,000
- Date
- 14 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 167,000
- Exercise price
- $15.31
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Footnote F3
The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 14, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.